In-hospital versus after-discharge complete revascularization in patients with ST segment elevation myocardial infarction and multivessel disease. REVIVA-ST trial
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0303284 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS ONE, 2024. Verfasst von Eva Rumiz und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, Consorcio Hospital General Universitario, Valencia, Spain. Hauptthemen laut MEDLINE: ST Elevation Myocardial Infarction, Patient Discharge, Percutaneous Coronary Intervention, Length of Stay. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Complete revascularization (CR) in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease (MVD), is associated with a reduction in major adverse cardiovascular events (MACE). However, there is uncertainty about whether nonculprit-lesion revascularization should be performed, during index hospitalization or delayed, especially regarding health care resources utilization. In this study, we aimed to evaluate the impact of in-hospital nonculprit-lesion revascularization vs. delayed (after discharge) revascularization on the length of index hospitalization.
Methods
In this single-center study, we randomly assigned patients with STEMI and MVD who underwent successful culprit-lesion PCI to a strategy of either CR during in-hospital admission or a delayed CR after discharge. The first primary endpoint was the length of hospital stay. The second endpoint was the composite of cardiovascular death, myocardial infarction or ischemia-driven revascularization at 12 months (MACE).
Results
From January 2018 to December 2022, we enrolled 258 patients (131 allocated to CR during in-hospital admission and 127 to an after-discharge CR). We found a significant reduction in the length of hospital stay in those assigned to after-discharge CR strategy [4 days (3–5) versus 7 days (5–9); p = 0.001]. At 12-month of follow-up, no differences were found in the occurrence of MACE, 7 (5.34%) patients in in-hospital CR and 4 (3.15%) in after-discharge CR strategy; (hazard ratio, 0.59; 95% confidence interval, 0.17 to 2.02; p = 0.397).
Conclusions
In STEMI patients with MVD, an after-discharge CR strategy reduces the length of index hospitalization without an increased risk of MACE after 12 months of follow-up.
Trial registration
ClinicalTrials.gov number: NCT04743154 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Cardiology Department, Consorcio Hospital General Universitario, Valencia, Spain.
- Cardiology Department, Hospital QuironSalud, Valencia, Spain.
- Universitat Jaume I, Castellón de la Plana, Spain.
- Cardiology Department, Hospital Clínico Universitario, INCLIVA, Universitat de València, Valencia, Spain.
- CIBER Cardiovascular, Madrid, Spain.
- Hospital Lluis Alcanyis, Xativa, Valencia, Spain.
ORCID-Profile: Eva Rumiz, Mauricio Pellicer, Julio Nuñez
Zitieren
APA
Rumiz, E., Valero, E., Fernandez, C., Vilar, J. V., Pellicer, M., Cubillos, A., Berenguer, A., Facila, L., Vaño, J., & Nuñez, J. (2024). In-hospital versus after-discharge complete revascularization in patients with ST segment elevation myocardial infarction and multivessel disease. REVIVA-ST trial. PLOS ONE. https://doi.org/10.1371/journal.pone.0303284
Vancouver
Rumiz E, Valero E, Fernandez C, Vilar JV, Pellicer M, Cubillos A, et al. In-hospital versus after-discharge complete revascularization in patients with ST segment elevation myocardial infarction and multivessel disease. REVIVA-ST trial. PLOS ONE. 2024. doi:10.1371/journal.pone.0303284
BibTeX
@article{Rumiz2024,
author = {Rumiz, Eva and Valero, Ernesto and Fernandez, Carmen and Vilar, Juan Vicente and Pellicer, Mauricio and Cubillos, Andres and Berenguer, Alberto and Facila, Lorenzo and Vaño, Joan and Nuñez, Julio},
title = {In-hospital versus after-discharge complete revascularization in patients with ST segment elevation myocardial infarction and multivessel disease. REVIVA-ST trial},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0303284}
}
EUVIMED